Cdc20 and securin overexpression predict short-term breast cancer survival

2014170 citationsJournal Articlehybrid Open Access

Authors

Henna Karra · University of Turku

Heli Repo · University of Turku

Ilmari Ahonen · University of Turku

Eliisa Löyttyniemi · University of Turku

Reino Pitkänen · Central Finland Health Care District

M. Lintunen · University of Turku

Teijo Kuopio ·

Abstract

We report for the first time the association of high Cdc20 and securin immunoexpression with extremely poor outcome of breast cancer patients. Our experience indicates that Cdc20 and securin are promising candidates for clinical applications in breast cancer prognostication, especially in the challenging prognostic decisions of TNBC.

Topics & Keywords

Microtubule and mitosis dynamics Cancer-related Molecular Pathways Wnt/β-catenin signaling in development and cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 110, Issue 12, pp. 2905-2913

DOI: 10.1038/bjc.2014.252

Field-Weighted Citation Impact: 5.01